Docosahexaenoic acid (DHA) supplementation attenuates changes in the concentration, phenotype, and response of immune peripheral blood cells in breast cancer patients undergoing neoadjuvant therapy. Secondary findings from the DHA-WIN trial
Supplementing DHA during breast cancer neoadjuvant chemotherapy improved systemic immune function by attenuating changes in blood cell concentrations, preventing depletion of immune cells, and enhancing ex vivo cytokine secretion after stimulation.
Authors
- Dhruvesh Patel (ORCID: https://orcid.org/0000-0003-0843-595X)
- Susan Goruk (ORCID: https://orcid.org/0000-0002-1531-0170)
- Marnie Newell (ORCID: https://orcid.org/0000-0001-5668-7698)
- Jaqueline Munhoz (ORCID: https://orcid.org/0000-0002-3112-3033)
- Anil A. Joy (ORCID: https://orcid.org/0000-0003-4201-8930)
- Denise G. Hemmings (ORCID: https://orcid.org/0000-0002-8051-9421)
- Gilbert Bigras (ORCID: https://orcid.org/0000-0003-1531-1496)
- Kerry S. Courneya (ORCID: https://orcid.org/0000-0002-9677-3918)
- Sunita Ghosh (ORCID: https://orcid.org/0000-0002-9763-5058)
- Vera C. Mazurak (ORCID: https://orcid.org/0000-0002-7724-6354)
- Catherine J. Field (ORCID: https://orcid.org/0000-0001-7285-4767)
Institutions
- University of Alberta (CA)
- Henry Ford Hospital (US)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2025-05-22
- DOI
- https://doi.org/10.1186/s13058-025-02048-z
- Citations
- 4
- Primary Topic
- Fatty Acid Research and Health
- Type
- article
- Field-Weighted Citation Impact
- 4.48
Funders
- Cancer Research Institute
- Children's Health Research Institute
- Patrick and Aimee Butler Family Foundation
- South Dakota Governor's Office of Economic Development
- University of Alberta
- Canadian Institutes of Health Research